BLAINTRAVENOUSINJECTABLE1 Generic Approved
Approved
Mar 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
TYENNE (tocilizumab-aazg) by Fresenius Kabi is interleukin 6 receptor antagonists [moa]. Approved for rheumatoid arthritis, juvenile idiopathic arthritis, giant cell arteritis and 14 more indications. First approved in 2024.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TYENNE (tocilizumab-aazg) is a monoclonal antibody targeting the interleukin-6 receptor, approved by the FDA on March 5, 2024, as a biosimilar or follow-on biologic. It treats 17 indications spanning autoimmune diseases (rheumatoid arthritis, giant cell arteritis), inflammatory conditions, oncology (lung cancer, breast cancer, multiple myeloma), and COVID-19-related inflammation. The drug works by blocking IL-6 signaling, a key driver of systemic inflammation and immune dysregulation.
Growth
Early-stage growth phase post-approval signals expansion in regulatory, commercial, and medical affairs headcount as market penetration accelerates.
Mechanism of Action
Interleukin 6 Receptor Antagonists
Pharmacologic Class:
Interleukin-6 Receptor Antagonist
Indications (17)
Worked on TYENNE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.